RCHA

Rich Pharmaceuticals (PK) Stock Price

0.0037
0.0003 (8.82%)
0.0037

Low
0.000001

52 Week Range

High
0.0046

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Rich Pharmaceuticals Inc (PK) RCHA OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0003 8.82% 0.0037 16:00:07
Open Price Low Price High Price Close Price Prev Close
0.004 0.0031 0.004 0.0037 0.0034
Bid Price Ask Price Spread News
0.0031 0.0042 0.0011 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
69 10,862,980 $ 0.00332 $ 36,064 - 0.000001 - 0.0046
Last Trade Time Type Quantity Stock Price Currency
15:46:29 60,000 $ 0.0037 USD

Rich Pharmaceuticals (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.67M 2.07B - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
35.68k $ - 0.00% - -

more financials information »

Rich Pharmaceuticals (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RCHA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00430.00440.00310.003814819,281,804-0.0006-13.95%
1 Month0.001950.00460.001490.003310425,871,1880.0017589.74%
3 Months0.00070.00460.00060.002143535,909,8300.003428.57%
6 Months0.00010.00460.0000010.00145127,352,2940.00363,600.0%
1 Year0.00010.00460.0000010.001200417,522,4300.00363,600.0%
3 Years0.00020.00460.0000010.000794210,473,9200.00351,750.0%
5 Years0.00010.00780.0000010.000696423,268,7690.00363,600.0%

Rich Pharmaceuticals (PK) Description

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.


Your Recent History
USOTC
RCHA
Rich Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.